Therefore, this study aimed to test the hypothesis that combining the SHP2 inhibitor, SHP099, with alectinib will result in synergistic ALK+ cell growth suppression in two different ALK+ NSCLC cell lines. Here, PTPN11 is linked to non-small cell lung carcinoma.